<DOC>
	<DOCNO>NCT02145637</DOCNO>
	<brief_summary>This phase Ib study investigate dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) afatinib ruxolitinib combination therapy , base preclinical data inhibition IL-6R/JAK1 signal transmission pathway increase sensitivity afatinib .</brief_summary>
	<brief_title>Phase I Study Combination Afatinib Ruxolitinib Patients With Treatment-refractory Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<criteria>1 . Stage 4 NSCLC patient 2. disease progression platinum doublet ( ) , EGFR TKI ( EGFR mutant ) , crizotinib ( ALK positive ) 3 . Men woman age 20 year old 4 . Recovery previous drugrelated toxicity : CTCAE 4.03 â‰¤ Grade 1 5 . ECOG 0 1 6. able orally take retain drug 7. measurable unmeasurable lesion RECIST 1.1 Criteria 8. proper hematological , renal , hepatic function 9. intention use acceptable contraception 10. able read understand inform consent form 1. previous chemotherapy , radiation therapy , immunotherapy , anticancer therapy within 14 day 2 . Clinically significant gastrointestinal disorder malabsorption syndrome 3 . Acute digestive disorder 4. major organ failure 5 . Significant cardiac disorder 6. major operation main organ 4 week 7 . Untreated symptomatic brain metastasis 8. pregnant nursing 9. previously diagnose Interstitial lung disease ( ILD ) 10. previously treat irreversible panHER inhibitor include Afatinib Ruxolitinib 11. previously experience hypersensitivity ingredient study drug 12. must receive CYP3A4 inducer inhibitor persistently study period . 13 . HIV positive active hepatitis 14. threaten patient 's safety predict</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cancer , Lung cancer , Head neck squamous cell carcinoma , Afatinib , Ruxolitinib , EGFR , JAK , STAT</keyword>
</DOC>